CJC-1295 / Ipamorelin: an evidence-first deep dive

Two randomized, placebo-controlled, double-blind ascending-dose studies examined CJC-1295 in healthy adults. After a single subcutaneous administration, mean GH increased for six days or more and mean IGF-1 remained elevated for roughly nine to eleven days.

The estimated half-life was 5.8 to 8.1 days. That prolonged profile is central to the study result, which is exactly why it should not be copied onto a short-acting no-DAC product with a similar commercial name.

An early dose-escalation study examined intravenous ipamorelin in healthy male volunteers. Ipamorelin showed dose-proportional pharmacokinetics with a terminal half-life of about two hours.

The GH response appeared as a single pulse, peaking at about 0.67 hours and then declining toward negligible concentrations. This establishes human GH-release pharmacology for ipamorelin; it does not establish body-composition, recovery or anti-ageing outcomes.

GHRH-receptor signalling and ghrelin-receptor signalling can both stimulate pituitary GH release through different upstream pathways. That creates a reasonable mechanistic rationale for studying them together.

But evidence for component A plus evidence for component B is not automatically evidence for combination A+B. To validate the marketed combination, the combination itself needs controlled human studies measuring relevant outcomes.

The CJC-1295 and ipamorelin studies primarily establish pharmacokinetics and hormone responses. They do not directly establish the downstream outcomes that dominate online marketing.

A hormone biomarker can explain that a pathway was engaged. Claims about muscle, fat, sleep, recovery or healthy ageing require outcome studies designed to measure those things.

Direct controlled human outcome trials of the widely marketed CJC no DAC + ipamorelin combination are sparse compared with the separate component pharmacology.

That gap should be visible on the page. The combination can be described as mechanistically plausible without pretending the popular regimen has the same evidence maturity as an approved endocrine treatment.

The controlled CJC-1295 study was short and the ipamorelin study focused on acute PK/PD. Neither establishes the long-term safety of repeated combined use in otherwise healthy people.

Commercial naming also creates product-identity risk: a vial labelled 'CJC-1295' may refer to DAC, no-DAC/Mod GRF(1-29), or unclear material. Evidence interpretation begins by establishing the actual molecule.